Delcath Systems, Inc.
HealthcareNASDAQ:DCTH · NASDAQ Capital Market
-$0.05 today
Vol 0.30M · Avg 0.41M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.4%
avg -490.0%
ROIC
0.5%
avg -45.8%
ROA
2.2%
avg -136.6%
Analysis
ROE is currently the strongest return metric at 2.4% versus its period average of -490.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gerard J. Michel | Chief Executive Officer & Director | $990,707.00 | — | 63 | $342,034.00 | 0.99% |
Vojislav Vukovic | Chief Medical Officer | $672,000.00 | — | 59 | $28,250.00 | 0.08% |
Martha S. Rook | Chief Operating Officer | $640,833.00 | — | 55 | $56,500.00 | 0.16% |
Johnny John | Senior Vice President of Clinical Operations & Medical Affairs | $472,163.00 | — | 61 | $22,500.00 | 0.07% |
Kevin Muir | Chief Commercial Officer | $394,402.00 | — | — | $56,500.00 | 0.16% |
Michael Brunner | Senior Vice President of Interventional Oncology | — | — | — | — | — |
David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer | — | — | 56 | $56,500.00 | 0.16% |
Sandra Pennell | Chief Financial Officer | — | — | 47 | $77,018.00 | 0.22% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$287,368.30
Sells
0
$0.00
Net Sentiment
+$287,368.30
Net buying
Most Active
MICHEL GERARD J
2 transactions
Analysis
Insiders reported 4 buys worth $287,368.30 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $287,368.30. MICHEL GERARD J was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +71.6% | +37.7% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +71.6% over three years. Forward estimates point to Revenue at +37.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Agilon Health, Inc.
NYSE:AGL
$1.88B
Tactile Systems Technology, Inc.
NASDAQ:TCMD
$593.46M
BrainsWay Ltd.
NASDAQ:BWAY
$573.83M
NeuroPace, Inc.
NASDAQ:NPCE
$533.23M
Cerus Corporation
NASDAQ:CERS
$512.94M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Semler Scientific, Inc.
SMLR
$310.75M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
RxSight, Inc.
NASDAQ:RXST
$194.98M
Nakamoto Inc.
NASDAQ:NAKA
$75.18M
Who manages DCTH?
Delcath Systems, Inc. (DCTH) lists 8 active executives. The top listed executive is Johnny John, Senior Vice President of Clinical Operations & Medical Affairs.
Are DCTH insiders buying or selling?
Recent insider activity shows net buying of $11.60B.
Explore More
Continue the stock analysis
Jump to another research area for this company.